卡博替尼治疗转移性非透明细胞肾细胞癌患者的回顾性分析
这项回顾性研究纳入2013年1月至2017年1月接受卡博替尼治疗的30例转移性非透明细胞肾细胞癌患者,中位随访20.6个月,中位无进展生存期8.6个月,中位总生存期25.4个月;28例可测量病灶患者中客观缓解率14.3%、疾病控制率78.6%;21例以60 mg/d起始者中12例(57.1%)因毒性需减量。
要点
- 30例转移性nccRCC患者接受卡博替尼,中位PFS 8.6个月,中位OS 25.4个月。
- 28例可测量病灶患者中客观缓解率14.3%,疾病控制率78.6%。
- 21例以60 mg/d起始者中12例(57.1%)因毒性需减量。
核心结论
- 在这项回顾性研究中,卡博替尼使转移性非透明细胞肾细胞癌患者获得有临床意义的获益,其中多数患者既往VEGFR-TKI治疗后出现疾病进展。
- 作者认为需要开展卡博替尼治疗非透明细胞肾细胞癌的前瞻性试验。
研究设计与样本
- 回顾性研究,纳入2013年1月至2017年1月接受卡博替尼治疗的30例非透明细胞肾细胞癌患者。
- 收集基线特征、毒性、减量、无进展生存期和总生存期资料。
- 由一名对患者病史和临床数据设盲的腹部影像学专科培训医师采用RECIST v1.1评估影像学缓解。
主要发现
- 中位随访20.6个月(95%CI:11.4-28.8),中位无进展生存期8.6个月(95%CI:6.1-14.7),中位总生存期25.4个月(95%CI:15.5-35.4)。
- 28例可测量病灶患者中,4例部分缓解(2例乳头状、1例嫌色细胞、1例未分类肾细胞癌),18例疾病稳定(64.2%),6例疾病进展(21.4%)。
- 客观缓解率为14.3%,疾病控制率为78.6%。
- 2例既往接受沙伏替尼治疗后疾病进展的乳头状肾细胞癌患者,接受卡博替尼后分别获得持久部分缓解和疾病稳定。
- 21例以60 mg/d起始卡博替尼的患者中,12例(57.1%)因毒性需要减量。
临床怎么用
- 原文未据此给出推荐。
- 作者认为需要开展卡博替尼治疗非透明细胞肾细胞癌的前瞻性试验。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cabozantinib prolongs overall survival (OS) and progression-free survival (PFS) in patients with metastatic clear cell renal cell carcinoma (RCC) that progressed on first-line vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFR-TKI). The role of cabozantinib has not been established in non-clear cell renal cell carcinoma (nccRCC). METHODS: This is a retrospective study of 30 patients with nccRCC who received cabozantinib from January 2013 to January 2017. Information collected included baseline characteristics, toxicity, dose reductions, PFS and OS. A fellowship trained abdominal radiologist, blinded to patient history and clinical data, assessed radiographic response using RECIST, v1.1. RESULTS: With a median follow-up of 20.6 months (95% confidence interval [CI]: 11.4-28.8), median PFS was 8.6 months (95% CI: 6.1-14.7), and median OS was 25.4 months (95% CI: 15.5-35.4). Of the 28 patients with measurable disease, 4 had partial responses (2 papillary, 1 chromophobe and 1 unclassified RCC), 18 had stable disease (64.2%) and 6 had progressive disease (21.4%), resulting in a 14.3% objective response rate and a 78.6% disease control rate. Two patients with papillary RCC who had experienced disease progression on savolitinib achieved durable partial response and stable disease, respectively, following treatment with cabozantinib. Of the 21 patients who started cabozantinib at 60 mg/d, 12 (57.1%) required dose reduction due to toxicity. CONCLUSION: In this retrospective study, cabozantinib produced a clinically meaningful benefit in patients with metastatic nccRCC, the majority of whom had disease progression on prior VEGFR-TKIs. Prospective trials of cabozantinib in nccRCC are warranted.
引用
- Campbell MT, Bilen MA, Shah AY, et al. Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis. Eur J Cancer. 2018. PMID: 30380460. doi:10.1016/j.ejca.2018.08.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。